A wealth of clinical evidence supports the safety of XIENCE™ Stent. It’s a decisive reason why interventional cardiologists (ICs) continue to be confident that the acute outcomes they observe in their patients will persist over the long term. XIENCE Skypoint™ Stent—with design improvements and a 48-mm stent option to treat long lesions—represents the latest generation among the XIENCE™ Stents.
XIENCE Skypoint™ Stent continues the legacy of outstanding safety outcomes of XIENCE™ Stent. It demonstrates consistency with optimal acute and early outcomes—in all types of patients and in complex lesions.2,3
| Types of Patients2,3 | Types of Lesions2,3 |
|---|---|
| Short DAPT | Bifurcations |
| Acute Myocardial Infarction (AMI) | Calcified Lesions |
| Diabetic | Long Lesions |
The 99% device success rate was the lowest success rate noted, even among a range of patient types in multiple clinical trials.2
Early outcomes in AMI patients revealed that XIENCE™ Stent showed significant improvement 2 weeks after percutaneous coronary intervention (PCI). For example, during that timeframe the findings demonstrated:
Representative OCT Images
XIENCE™ Stent also demonstrates safety among ST-elevation myocardial infarction (STEMI) patients, a subgroup of AMI patients. At 30 days, the rate of definite stent thrombosis (ST) with XIENCE™ Stent vs bare metal stents (BMS) was significantly lower: 0.4% vs 1.6%, p = 0.02.5
Definite ST in STEMI Patients
In other types of complex patients, early (30-day) outcomes reveal very low rates of definite ST. This includes patients with bifurcations, calcified lesions, and long lesions.
Definite ST – 30 Days
XIENCE™ Stent has significantly lower rates of acute and early ST than Synergy‡ and Resolute‡ DES.9,10
There is a 75% lower rate of acute (24-hour) definite ST with XIENCE™ Stent vs Synergy‡.9
Acute Definite Stent Thrombosis
There is an 88% lower rate of early (30-day) definite ST with XIENCE™ Stent vs Resolute‡.10
Definite Stent Thrombosis 30 Day
Platelet adhesion is a key factor in stent thrombosis, and the XIENCE™ Stent’s unique, durable fluoropolymer was created to ensure long-term protection from thrombosis.
Preclinical testing confirms that the XIENCE™ Stent exhibits the least platelet adhesion compared to other DES (p < 0.01). This factor protects patients from short-term complications.11
One-year subgroup analysis data from the STOPDAPT-2 trial showed excellent patient outcomes for high bleeding risk (HBR) patients using 1-month dual antiplatelet therapy (DAPT). Patients at high bleeding risk who followed a 1-month DAPT regimen had significantly lower event rates than those using a 12-month DAPT strategy.
Extensive evidence demonstrates that XIENCE™ Stents deliver unparalleled patient outcomes which last far beyond the intervention. Data from multiple studies support these exceptional results.
MAT-2107574 v3.0
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0
